Fitzgerald TF - Search Results

1

Regional disparities in breast cancer outcomes and the process of care.

Weber JJ, Kachare SD, Vohra NA, Fitzgerald TF, Wong JH. Weber JJ, et al. Among authors: fitzgerald tf. Am Surg. 2014 Jul;80(7):669-74. Am Surg. 2014. PMID: 24987898

2

Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.

Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Xu C, et al. Dermatology. 2022;238(3):438-447. doi: 10.1159/000519176. Epub 2021 Oct 28. Dermatology. 2022. PMID: 34710876

3

Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.

Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Xu C, et al. J Dermatolog Treat. 2022 Jun;33(4):2270-2277. doi: 10.1080/09546634.2021.1950600. Epub 2022 Jan 20. J Dermatolog Treat. 2022. PMID: 34264149 Free article.

4

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.

Teeple A, Fitzgerald T. Teeple A, et al. J Dermatolog Treat. 2022 Feb;33(1):518-524. doi: 10.1080/09546634.2020.1770172. Epub 2020 Jun 4. J Dermatolog Treat. 2022. PMID: 32479140 Free article.

5

Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real-world data.

Li N, Teeple A, Muser E, Lucas J, Hetherington J, Fitzgerald T. Li N, et al. Clin Exp Dermatol. 2020 Jul;45(5):572-575. doi: 10.1111/ced.14142. Epub 2019 Dec 21. Clin Exp Dermatol. 2020. PMID: 31736108

6

Characteristics of Patients Initiating Guselkumab for Plaque Psoriasis in the Symphony Health Claims Database.

Fitzgerald T, Teeple A, Slaton T, Kozma CM. Fitzgerald T, et al. J Drugs Dermatol. 2021 Oct 1;20(10):1127-1131. doi: 10.36849/JDD.6024. J Drugs Dermatol. 2021. PMID: 34636519

7

Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies.

Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD. Walsh JA, et al. Curr Med Res Opin. 2020 Jul;36(7):1245-1252. doi: 10.1080/03007995.2020.1754186. Epub 2020 Apr 23. Curr Med Res Opin. 2020. PMID: 32271088 Free article.

8

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.

Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B. Fitzgerald T, et al. Biologics. 2021 Jan 6;15:1-15. doi: 10.2147/BTT.S285610. eCollection 2021. Biologics. 2021. PMID: 33442230 Free PMC article.

9

Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.

Walsh JA, Callis Duffin K, Van Voorhees AS, Chakravarty SD, Fitzgerald T, Teeple A, Rowland K, Uy J, McLean RR, Malley W, Cronin A, Merola JF. Walsh JA, et al. Dermatol Ther (Heidelb). 2022 Jan;12(1):97-119. doi: 10.1007/s13555-021-00637-2. Epub 2021 Nov 25. Dermatol Ther (Heidelb). 2022. PMID: 34822121 Free PMC article.

10

Formation and Expansion of Memory B Cells against Coronavirus in Acutely Infected COVID-19 Individuals.

Embong AK, Nguyen-Contant P, Wang J, Kanagaiah P, Chaves FA, Fitzgerald TF, Zhou Q, Kosoy G, Branche AR, Miller BL, Zand MS, Sangster MY, Topham DJ. Embong AK, et al. Among authors: fitzgerald tf. Pathogens. 2022 Jan 29;11(2):186. doi: 10.3390/pathogens11020186. Pathogens. 2022. PMID: 35215130 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters